...
首页> 外文期刊>The American Journal of Psychiatry >Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study
【24h】

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study

机译:二甲双胍的添加减轻了单纯用药的初发精神分裂症患者中奥氮平诱导的体重增加:一项双盲,安慰剂对照的研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to assess the efficacy of metformin in preventing olanzapine-induced weight gain. Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N= 20). This investigation was conducted in a double-blind fashion. Planned assessments included body weight, body mass index, proportion of patients who gained more than 7% of their baseline weight at the end of the 12-week treatment, waist circumference, waist-to-hip ratio, fasting glucose and insulin, insulin resistance index, and scores on the Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS). Of the 40 patients who were randomly assigned, 37 (92.5%) completed treatments. The weight, body mass index, waist circumference, and waist-to-hip ratio levels increased less in the olanzapine plus metformin group relative to the olanzapine plus placebo group during the 12-week follow-up period. The insulin and insulin resistance index values of the olanzapine plus placebo group increased significantly at weeks 8 and 12. In contrast, the insulin and insulin resistance index levels of the olanzapine plus metformin group remained unchanged. Significantly fewer patients in the olanzapine plus metformin group relative to patients in the olanzapine plus placebo group increased their baseline weight by more than 7%, which was the cutoff for clinically meaningful weight gain. There was a significant decrease in SAPS and SANS scores within each group from baseline to week 12, with no between-group differences. Metformin was tolerated well by all patients. Metformin was effective and safe in attenuating olanzapine-induced weight gain and insulin resistance in drug-naive first-episode schizophrenia patients. Patients displayed good adherence to this type of preventive intervention.
机译:这项研究的目的是评估二甲双胍在预防奥氮平诱导的体重增加中的功效。 40名精神分裂症患者被随机分配接受奥氮平15毫克/天,二甲双胍,750毫克/天(N = 20)或奥氮平15毫克/天,安慰剂(N = 20)治疗12周。该调查以双盲方式进行。计划的评估包括体重,体重指数,在12周治疗后体重增加超过基线体重7%的患者比例,腰围,腰臀比,空腹血糖和胰岛素,胰岛素抵抗指数,以及阳性症状评估量表(SAPS)和阴性症状评估量表(SANS)的得分。在随机分配的40位患者中,有37位(92.5%)完成了治疗。在12周的随访期内,与奥氮平加安慰剂组相比,奥氮平加二甲双胍组的体重,体重指数,腰围和腰臀比水平增加的幅度较小。奥氮平加安慰剂组的胰岛素和胰岛素抵抗指数值在第8周和第12周显着增加。相反,奥氮平加二甲双胍组的胰岛素和胰岛素抵抗指数水平保持不变。与奥氮平加安慰剂组相比,奥氮平加二甲双胍组的患者明显少得多,其基线体重增加了7%以上,这是具有临床意义的体重增加的临界值。从基线到第12周,每组的SAPS和SANS得分均显着下降,而组间无差异。所有患者对二甲双胍的耐受性良好。二甲双胍可有效和安全地减轻初治精神分裂症患者的奥氮平诱导的体重增加和胰岛素抵抗。患者表现出对这种预防性干预的良好依从性。

著录项

  • 来源
    《The American Journal of Psychiatry》 |2008年第3期|p.352-358|共7页
  • 作者单位

    Ren-RongWu, M.D.Jing-Ping Zhao, M.D.Xiao-Feng Guo, M.D.Yi-Qun He, M.D.Mao-Sheng Fang, M.D.Wen-Bin Guo, M.D.Jin-Dong Chen, M.D.Le-Hua Li, M.D.Received Jan. 12, 2007, revisions received April 13, June 12, July 24, and Aug. 17, 2007, accepted Aug. 20, 2007 (doi: 10.1176/ appi.ajp.2007.07010079). From the Institute of Mental Health of the Second Xiangya Hospital, Central South University, Changsha, China. Address correspondence and reprint requests to Dr. Zhao, Institute of Mental Health of the second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha 410011, Hunan, China, zhaojingpinghunan@yahoo.com.cn (e-mail).The authors report no competing interests.Supported by National Key Technologies R&D Program in the 10th 5-year-plan grant 2004BA720A22 (Dr. Zhao) from the Ministry of Science and Technology of the People's Republic of China.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号